Revenue growth remains highly erratic, while gross margins have struggled to exceed 57.7%, falling short of the 60-70% range typical for mature medical device peers.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 |
|---|
| Sales/Revenue | 1.03B | 1.01B | 940.2M | 747.72M | 801.22M | 702.8M | 498.83M | 362.31M | 183.87M | 107.6M | 84.25M | 72.85M | 49.72M | 29.01M | 2.47M | 0 |
| Revenue Growth % | -6.78% | 7.93% | 25.74% | -6.68% | 14% | 40.89% | 37.68% | 97.05% | 70.88% | 27.72% | 15.65% | 46.51% | 71.42% | 1072.13% | - | - |
| Cost of Goods Sold | 463.14M | 483.89M | 450.63M | 380.03M | 388.23M | 326.58M | 238.31M | 168.09M | 94.04M | 63.51M | 60.66M | 46.27M | 34.47M | 22.84M | 3.82M | 0 |
| COGS % of Revenue | - | 47.69% | 47.93% | 50.82% | 48.46% | 46.47% | 47.77% | 46.4% | 51.15% | 59.02% | 72% | 63.51% | 69.33% | 78.74% | 154.48% | - |
| Gross Profit | 564.39M | 530.85M | 489.57M | 367.69M | 412.99M | 376.21M | 260.52M | 194.21M | 89.82M | 44.09M | 23.59M | 26.58M | 15.25M | 6.17M | -1.35M | 0 |
| Gross Margin % | 54.93% | 52.31% | 52.07% | 49.18% | 51.54% | 53.53% | 52.23% | 53.6% | 48.85% | 40.98% | 28% | 36.49% | 30.67% | 21.26% | -54.48% | - |
| Gross Profit Growth % | - | 8.43% | 33.15% | -10.97% | 9.77% | 44.41% | 34.14% | 116.22% | 103.71% | 86.9% | -11.24% | 74.32% | 147.28% | 557.36% | - | - |
| Operating Expenses | 645.41M | 608.97M | 588.7M | 600.92M | 505.83M | 353.56M | 268.48M | 210.93M | 134.45M | 107.04M | 101.64M | 95.58M | 90.91M | 55.6M | 31.7M | 24.21M |
| OpEx % of Revenue | - | 60.01% | 62.61% | 80.37% | 63.13% | 50.31% | 53.82% | 58.22% | 73.13% | 99.48% | 120.65% | 131.21% | 182.84% | 191.68% | 1280.96% | - |
| Selling, General & Admin | 437.36M | 434.13M | 389.82M | 352.5M | 335.68M | 261.51M | 204.9M | 165.74M | 105.23M | 86.38M | 82.83M | 78.62M | 75.12M | 44.52M | 22.69M | 15.95M |
| SG&A % of Revenue | - | 42.78% | 41.46% | 47.14% | 41.9% | 37.21% | 41.08% | 45.74% | 57.23% | 80.28% | 98.32% | 107.92% | 151.08% | 153.49% | 916.91% | - |
| Research & Development | 188.1M | 174.84M | 198.88M | 248.42M | 170.15M | 92.05M | 63.57M | 45.2M | 29.23M | 20.66M | 18.81M | 16.96M | 15.79M | 11.08M | 9.01M | 8.26M |
| R&D % of Revenue | - | 17.23% | 21.15% | 33.22% | 21.24% | 13.1% | 12.74% | 12.48% | 15.9% | 19.2% | 22.33% | 23.28% | 31.76% | 38.2% | 364.05% | - |
| Other Operating Expenses | 1000K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -81.01M | -78.12M | -99.13M | -233.23M | -92.85M | 22.65M | -7.96M | -16.72M | -44.63M | -62.94M | -78.05M | -69M | -75.66M | -49.43M | -33.05M | -24.21M |
| Operating Margin % | -7.88% | -7.7% | -10.54% | -31.19% | -11.59% | 3.22% | -1.6% | -4.62% | -24.27% | -58.5% | -92.64% | -94.72% | -152.17% | -170.42% | -1335.44% | - |
| Operating Income Growth % | - | 21.19% | 57.5% | -151.2% | -509.87% | 384.69% | 52.42% | 62.53% | 29.09% | 19.36% | -13.11% | 8.8% | -53.06% | -49.58% | -36.5% | - |
| EBITDA | -67.66M | -60.46M | -98.97M | -217.51M | -78.52M | 36.5M | 2.49M | -10.65M | -38.81M | -56.08M | -72.56M | -64.17M | -71.28M | -46.27M | -31.02M | -22.94M |
| EBITDA Margin % | -6.58% | -5.96% | -10.53% | -29.09% | -9.8% | 5.19% | 0.5% | -2.94% | -21.11% | -52.12% | -86.13% | -88.09% | -143.35% | -159.51% | -1253.32% | - |
| EBITDA Growth % | 58.09% | 38.91% | 54.5% | -177.03% | -315.13% | 1363.43% | 123.42% | 72.56% | 30.79% | 22.72% | -13.07% | 9.96% | -54.05% | -49.17% | -35.23% | - |
| D&A (Non-Cash Add-back) | 13.36M | 17.67M | 158K | 15.71M | 14.33M | 13.85M | 10.45M | 6.07M | 5.82M | 6.87M | 5.49M | 4.83M | 4.39M | 3.17M | 2.03M | 1.28M |
| EBIT | -88.94M | -192.37M | -99.28M | -212.18M | -88.54M | 20.21M | -23.48M | -24.53M | -115M | -61.68M | -77.75M | -68.67M | -75.55M | -58.43M | -30.49M | -24.97M |
| Net Interest Income | -1.46M | 1.18M | 10.58M | 12.98M | -151K | -5.37M | -11.24M | 3.19M | -6.12M | -11.1M | -5.41M | -3.4M | -3.79M | -4.7M | -2.52M | -528.52K |
| Interest Income | 3.02M | 9.09M | 17.99M | 22.86M | 6.06M | 674K | 1.57M | 3.27M | 1.46M | 239K | 296K | 337K | 112K | 6.64K | 2.42K | 13.66K |
| Interest Expense | 4.47M | 7.91M | 7.42M | 9.88M | 6.21M | 6.04M | 12.8M | 78K | 7.58M | 11.34M | 5.71M | 3.74M | 3.9M | 4.71M | 2.53M | 542.17K |
| Other Income/Expense | -17.05M | -122.15M | 7.26M | 12.98M | -4K | -6.75M | -28.32M | -7.88M | -77.93M | -10.08M | -5.41M | -3.4M | -3.79M | -13.7M | 33K | -1.3M |
| Pretax Income | -98.06M | -200.27M | -91.87M | -220.25M | -92.85M | 15.9M | -36.28M | -24.6M | -122.56M | -73.03M | -83.46M | -72.41M | -79.45M | -63.14M | -33.02M | -25.51M |
| Pretax Margin % | -9.54% | -19.74% | -9.77% | -29.46% | -11.59% | 2.26% | -7.27% | -6.79% | -66.66% | -67.87% | -99.07% | -99.39% | -159.79% | -217.67% | -1334.11% | - |
| Income Tax | -3.51M | 4.44M | 4.16M | 2.36M | 1.74M | 335K | -1.9M | 149K | 51K | 8K | -15K | 10K | 71K | 4.71M | 2.53M | 0 |
| Effective Tax Rate % | 3.58% | -2.22% | -4.52% | -1.07% | -1.88% | 2.11% | 5.24% | -0.61% | -0.04% | -0.01% | 0.02% | -0.01% | -0.09% | -7.46% | -7.65% | 0% |
| Net Income | -94.55M | -204.71M | -96.03M | -222.61M | -94.59M | 15.57M | -34.38M | -24.75M | -122.61M | -73.03M | -83.45M | -72.42M | -79.52M | -63.14M | -33.02M | -25.51M |
| Net Margin % | -9.2% | -20.17% | -10.21% | -29.77% | -11.81% | 2.21% | -6.89% | -6.83% | -66.69% | -67.87% | -99.05% | -99.41% | -159.94% | -217.67% | -1334.11% | - |
| Net Income Growth % | 48.58% | -113.18% | 56.86% | -135.33% | -707.7% | 145.27% | -38.9% | 79.81% | -67.88% | 12.48% | -15.23% | 8.94% | -25.95% | -91.24% | -29.42% | - |
| Net Income (Continuing) | -94.55M | -204.71M | -96.03M | -222.61M | -94.59M | 15.57M | -34.38M | -24.75M | -122.61M | -73.03M | -83.45M | -72.42M | -79.52M | -63.14M | -33.02M | -25.51M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.38 | -3.04 | -1.47 | -3.43 | -1.47 | 0.24 | -0.56 | -0.42 | -2.55 | -12.86 | -27.30 | -25.04 | -34.17 | -27.53 | -26.32 | -20.34 |
| EPS Growth % | 49.66% | -106.8% | 57.14% | -133.33% | -712.5% | 142.86% | -33.33% | 83.53% | 80.17% | 52.89% | -9.03% | 26.72% | -24.12% | -4.6% | -29.4% | - |
| EPS (Basic) | - | -3.04 | -1.47 | -3.43 | -1.47 | 0.25 | -0.56 | -0.42 | -2.55 | -12.86 | -27.30 | -25.04 | -34.17 | -27.53 | -26.32 | -20.34 |
| Diluted Shares Outstanding | 68.4M | 67.28M | 65.45M | 64.97M | 64.15M | 64.35M | 60.99M | 58.51M | 48.13M | 5.68M | 3.06M | 2.89M | 2.33M | 2.29M | 1.25M | 1.25M |
| Basic Shares Outstanding | 68.4M | 67.28M | 65.45M | 64.9M | 64.15M | 63M | 60.99M | 58.51M | 48.13M | 5.68M | 3.06M | 2.89M | 2.33M | 2.29M | 1.25M | 1.25M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Limited liquidity and competition
As reported in recent financial statements, TNDM's revenue growth has exhibited significant volatility, fluctuating from a 95.7% surge in 2024Q3 to a 31.4% contraction in 2025Q3, suggesting that the company's top-line expansion remains highly sensitive to product launch cycles and competitive pressures in the insulin pump market.
The erratic revenue trajectory appears to reflect the challenges of maintaining market share against tubeless competitors while navigating the transition to the Mobi platform. Investors should monitor whether the current 5.5% growth rate in 2026Q1 represents a stabilization or a structural deceleration in the company's ability to capture new patient starts.
According to historical income statement data, TNDM's gross margins have struggled to surpass the 55% threshold, peaking at 57.7% in 2025Q4, which remains notably below the 60-70% range typically observed among more mature medical device peers like DexCom and Insulet Corporation.
The inability to consistently scale gross margins suggests that manufacturing complexities and the logistical costs of the disposable supply chain continue to exert downward pressure on profitability. This margin profile warrants further investigation into whether the Mobi platform can eventually drive the cost efficiencies necessary to achieve sustainable operating leverage.
Based on reported figures, TNDM has failed to demonstrate consistent operating leverage, as evidenced by the 2025Q1 period where operating expenses ballooned to $125.4M in R&D alone, resulting in a deeply negative operating margin of -51.6% that highlights the company's heavy reliance on high fixed-cost investments.
The persistent disconnect between gross profit generation and operating expense management suggests that the company has not yet reached the critical mass required to achieve profitability. The recurring nature of SG&A and R&D spending appears to be outpacing revenue growth, which may indicate that the current business model requires significant scale to reach break-even.
Analysis of recent SEC filings indicates that TNDM's net income is frequently impacted by substantial stock-based compensation, which reached $25.6M in 2025Q2, effectively masking the underlying operational cash burn and complicating the assessment of true economic profitability for shareholders.
The reliance on equity-based incentives in a period of negative net income suggests that the company is prioritizing talent retention at the expense of shareholder dilution. Investors should monitor the impact of these non-cash charges on the overall capital structure, especially given the company's limited cash position.
As indicated by the company's financial disclosures, the combination of a $90.6M cash balance and a -20.17% net margin suggests that TNDM faces a precarious liquidity position that may necessitate dilutive financing if operational cash flow does not improve significantly within the next several quarters.
Short-sellers may focus on the potential for a liquidity crunch if the Mobi launch fails to gain sufficient traction to offset the high cash burn rate. The company's reliance on external capital markets appears to be a significant risk factor that could lead to further equity dilution if the current growth trajectory does not accelerate.
Quick answers to the most common questions about buying TNDM stock.
For fiscal year 2025, Tandem Diabetes Care, Inc. (TNDM) reported total revenue of $1.01B.
Tandem Diabetes Care, Inc. (TNDM) reported a net loss of $204.7M for the fiscal year ending 2025.
Tandem Diabetes Care, Inc. (TNDM) reported an operating income of $-78.1M, resulting in an operating profit margin of -7.7%. This margin reflects the operational efficiency of the business before interest and taxes.
Tandem Diabetes Care, Inc. (TNDM) generated $530.8M in gross profit for the year, representing a gross profit margin of 52.3%. This demonstrates the company's core pricing power and production efficiency.